OpGen’s stock soars after Curetis sub obtains CE mark certification in the EU for COVID-19 test

/ / News

Shares of Maryland-based OpGen Inc. rocketed 43% in active premarket trading Thursday, after the molecular diagnostics company said its Germany-based Curetis GmbH subsidiary obtained the CE mark certification in the European Union for its SARS-CoV-2 test kit. Trading volume was 5.4 million shares, already more than half the full-day average of 9.7 million shares. The uses mouth and nose swabs to test people suspected of COVID-19 by their health care provider or for screening of asymptomatic individuals. “By launching this new product in Europe, we are committed to helping our distributors and customers to expand the availability of SARS-CoV-2 diagnostic testing, and our own-developed CE-IVD marked SARS-CoV-2 Kit with PULB is expected to help increase availability of these much-needed tests,” said OpGen Chief Executive Oliver Schacht. The stock has run up 81.4% year to date through Wednesday, while the S&P 500 has gained 4.5%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.